ADC Therapeutics (NYSE: ADCT) Exceeds Q3 2026 Earnings Expectations with ZYNLONTA Growth
Adjusted loss per share of $0.16 was smaller than the $0.21 analyst estimate. Revenue reached $21.72 million, surpassing the $18.7 million estimate. ADC Therapeutics holds $189.2 million in cash, extending its operational funding into 2029. ADC Therapeutics (NYSE: ADCT) is a drug company…